VIRGINIA MARYANN LUPARELLO-RAGUSA

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family PAWLING, NY NPI 1942947734

General Payments — all program years on this page

$2,203.36

  • Category: General Payments
  • Program years: PY2023–2024
  • Record count: 55
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $1,581.91 across 36 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $801.3928
Long term medical supply or device loan $681.537
Education $98.991

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2023 $621.4519
2024 $1,581.9136

Records — PY2024 (36)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087147160 Novartis Pharmaceuticals Corporation $99.70 01/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1087147162 Novartis Pharmaceuticals Corporation $99.70 02/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1087147164 Novartis Pharmaceuticals Corporation $99.70 03/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1087147166 Novartis Pharmaceuticals Corporation $99.70 04/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1087147168 Novartis Pharmaceuticals Corporation $99.70 05/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1087147174 Novartis Pharmaceuticals Corporation $99.70 06/13/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1087147180 Novartis Pharmaceuticals Corporation $83.33 07/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1089450358 Daiichi Sankyo Inc. $15.71 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089450360 Daiichi Sankyo Inc. $27.12 02/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1091955913 Ipsen Biopharmaceuticals, Inc $19.89 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1091955915 Ipsen Biopharmaceuticals, Inc $23.85 03/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1091955917 Ipsen Biopharmaceuticals, Inc $15.53 08/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101172186 Celgene Corporation $19.69 01/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101172196 Celgene Corporation $23.43 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104210391 AstraZeneca Pharmaceuticals LP $18.14 04/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104359201 AstraZeneca Pharmaceuticals LP $17.57 06/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104359571 AstraZeneca Pharmaceuticals LP $21.18 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104436955 AstraZeneca Pharmaceuticals LP $16.14 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104626874 AstraZeneca Pharmaceuticals LP $98.99 04/30/2024 Education Undisputed 01/23/2026 View at CMS
1104738387 AstraZeneca Pharmaceuticals LP $20.42 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105563048 AstraZeneca Pharmaceuticals LP $15.08 04/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105847305 AstraZeneca Pharmaceuticals LP $3.42 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107566444 ABBVIE INC. $28.71 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107566446 ABBVIE INC. $15.18 03/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107566448 ABBVIE INC. $24.44 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107566450 ABBVIE INC. $33.34 08/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114335187 Regeneron Healthcare Solutions, Inc. $24.54 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117615442 Amgen Inc. $125.00 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120854289 BeiGene USA, Inc. $108.05 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133668726 Gilead Sciences, Inc. $30.83 03/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139982240 GENZYME CORPORATION $32.13 03/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139982280 GENZYME CORPORATION $38.08 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141219080 Incyte Corporation $15.89 03/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144979236 Takeda Pharmaceuticals U.S.A., Inc. $25.61 01/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145541934 Karyopharm Therapeutics Inc. $17.76 03/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151319121 JAZZ PHARMACEUTICALS INC. $24.66 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.